{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:32:51Z","timestamp":1791196371993,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.euroneuro.2015.06.011","type":"journal-article","created":{"date-parts":[[2015,6,22]],"date-time":"2015-06-22T20:47:22Z","timestamp":1435006042000},"page":"1767-1774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Second-generation antipsychotics and adiponectin levels in schizophrenia: A comparative meta-analysis"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2612-4119","authenticated-orcid":false,"given":"Francesco","family":"Bartoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Crocamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Clerici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Carr\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2015.06.011_bib1","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.4088\/JCP.v68n1202","article-title":"Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia","volume":"68","author":"Bai","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.03.014","article-title":"Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study","volume":"111","author":"Bai","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/met.2013.0010","article-title":"Metabolic syndrome in people suffering from posttraumatic stress disorder: a systematic review and meta-analysis","volume":"11","author":"Bartoli","year":"2013","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib4","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/appi.ajp.2013.13040447","article-title":"Bipolar disorder, schizophrenia, and metabolic syndrome","volume":"170","author":"Bartoli","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.psyneuen.2015.03.012","article-title":"Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: a meta-analysis","volume":"56","author":"Bartoli","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jpsychires.2015.04.028","article-title":"Schizoaffective disorder and metabolic syndrome: a meta-analytic comparison with schizophrenia and other non-affective psychoses","volume":"66","author":"Bartoli","year":"2015","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JCP.0b013e31819b95fc","article-title":"Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions","volume":"29","author":"Birkenaes","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/WNF.0b013e31824d5288","article-title":"Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies","volume":"35","author":"Bou Khalil","year":"2012","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib9","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s00127-014-0835-y","article-title":"The prevalence of metabolic syndrome in people with severe mental illness: a mediation analysis","volume":"49","author":"Carr\u00e0","year":"2014","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib10","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.genhosppsych.2014.08.005","article-title":"Cardiovascular risk factors among people with severe mental illness in Italy: a cross-sectional comparative study","volume":"36","author":"Clerici","year":"2014","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.annepidem.2010.10.011","article-title":"Serum adiponectin in relation to body mass index and other correlates in black and white women","volume":"21","author":"Cohen","year":"2011","journal-title":"Ann. Epidemiol."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molmed.2010.10.010","article-title":"Antipsychotic drugs and obesity","volume":"17","author":"Correll","year":"2011","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib13","series-title":"Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series","article-title":"Analysing Data and Undertaking Meta-Analyses","author":"Deeks","year":"2008"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/j.2051-5545.2009.tb00199.x","article-title":"Metabolic syndrome in people with schizophrenia: a review","volume":"8","author":"De Hert","year":"2009","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib15","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.clnu.2004.04.010","article-title":"Adiponectin, the missing link in insulin resistance and obesity","volume":"23","author":"Gil-Campos","year":"2004","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.schres.2008.09.008","article-title":"A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder","volume":"106","author":"Hanssens","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib17","first-page":"15","article-title":"Hyperglycemia and antipsychotic medications","volume":"62","author":"Haupt","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.schres.2007.11.026","article-title":"Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin","volume":"100","author":"Jin","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.febslet.2007.11.070","article-title":"The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS","volume":"582","author":"Kadowaki","year":"2008","journal-title":"FEBS Lett."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1559-4572.2008.00030.x","article-title":"The role of adiponectin in obesity, diabetes, and cardiovascular disease","volume":"4","author":"Kawano","year":"2009","journal-title":"J. Cardiometab. Syndr."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib22","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ejim.2012.06.013","article-title":"The plasma leptin\/adiponectin ratio predicts first cardiovascular event in men: a prospective nested case-control study","volume":"23","author":"Kappelle","year":"2012","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.psychres.2014.04.049","article-title":"Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine","volume":"218","author":"Klemettil\u00e4","year":"2014","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/1471-244X-11-173","article-title":"Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics\u2014results from a German observational study","volume":"11","author":"Kraemer","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib25","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jclinepi.2005.03.004","article-title":"Searching one or two databases was insufficient for meta-analysis of observational studies","volume":"58","author":"Lemeshow","year":"2005","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib26","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib27","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jama.2009.976","article-title":"Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis","volume":"302","author":"Li","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1467-789X.2005.00159.x","article-title":"Adiponectin: action, regulation and association to insulin sensitivity","volume":"6","author":"Lihn","year":"2005","journal-title":"Obes. Rev."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/met.2011.0123","article-title":"The impact of leptin and adiponectin on incident type 2 diabetes is modified by sex and insulin resistance","volume":"10","author":"Lilja","year":"2012","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1515\/hmbci-2013-0053","article-title":"The role of leptin\/adiponectin ratio in metabolic syndrome and diabetes","volume":"18","author":"L\u00f3pez-Jaramillo","year":"2014","journal-title":"Horm. Mol. Biol. Clin. Investig."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pnpbp.2014.12.001","article-title":"Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin","volume":"58","author":"Lu","year":"2015","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib32","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1006\/bbrc.1996.0587","article-title":"cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1(AdiPose Most abundant Gene transcript 1)","volume":"221","author":"Maeda","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.beem.2013.06.008","article-title":"Clinical use of adiponectin as a marker of metabolic dysregulation","volume":"2014","author":"Mather","year":"2014","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib34","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1089\/met.2010.0053","article-title":"Metabolic syndrome in severe mental disorders","volume":"9","author":"Ohaeri","year":"2011","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib37","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.2337\/dc09-1130","article-title":"Changes in serum adiponectin concentrations correlate with changes in BMI, waist circumference, and estimated visceral fat area in middle-aged general population","volume":"32","author":"Okauchi","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5152\/eajm.2011.08","article-title":"The effects of atypical antipsychotic usage duration on serum adiponectin levels and other metabolic parameters","volume":"43","author":"Oral","year":"2011","journal-title":"Eurasian J. Med."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib39","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.diabet.2008.03.003","article-title":"Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study","volume":"34","author":"Oriot","year":"2008","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib40","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2337\/dc11-2055","article-title":"Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies","volume":"35","author":"Pan","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib41","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/JCP.0b013e318172b8e6","article-title":"Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment","volume":"28","author":"Perez-Iglesias","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib42","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1001\/jama.291.14.1730","article-title":"Plasma adiponectin levels and risk of myocardial infarction in men","volume":"291","author":"Pischon","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib43","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.atherosclerosis.2011.07.011","article-title":"Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women","volume":"219","author":"Pischon","year":"2011","journal-title":"Atherosclerosis"},{"issue":"3 Suppl. 2","key":"10.1016\/j.euroneuro.2015.06.011_bib44","first-page":"S26","article-title":"Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis","volume":"60","author":"Potvin","year":"2015","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib45","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/01.jcp.0000218404.64619.52","article-title":"Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia","volume":"26","author":"Richards","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib46","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2165\/11596300-000000000-00000","article-title":"Atypical antipsychotic-induced weight gain: insights into mechanisms of action","volume":"25","author":"Roerig","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib47","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/schbul\/sbm141","article-title":"Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review","volume":"34","author":"Sentissi","year":"2008","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib48","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1600-0447.2008.01334.x","article-title":"Which comes first: atypical antipsychotic treatment or cardiometabolic risk?","volume":"119","author":"Stahl","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib49","series-title":"Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series","article-title":"Addressing Reporting Biases","author":"Sterne","year":"2008"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib50","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib51","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00004850-200401000-00007","article-title":"Serum adiponectin concentrations during treatment with olanzapine or risperidone: a pilot study","volume":"19","author":"Togo","year":"2004","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib52","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3109\/13651501.2010.550400","article-title":"Association of serum levels of leptin, ghrelin, and adiponectin in schizophrenic patients and healthy controls","volume":"15","author":"Tsai","year":"2011","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib53","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4088\/JCP.v69n0320","article-title":"Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder","volume":"69","author":"van Winkel","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib54","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1176\/appi.ajp.2012.12050620","article-title":"Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators","volume":"170","author":"Vancampfort","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib55","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1471-2288-9-80","article-title":"Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data","volume":"9","author":"Wallace","year":"2009","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.euroneuro.2011.03.010","article-title":"Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study","volume":"22","author":"Wampers","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.06.011_bib57","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5498\/wjp.v4.i4.103","article-title":"Peptides from adipose tissue in mental disorders","volume":"4","author":"W\u0119drychowicz","year":"2014","journal-title":"World J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.06.011_bib58","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/MAJ.0b013e318262dbef","article-title":"Adiponectin levels and risk of coronary heart disease: a meta-analysis of prospective studies","volume":"345","author":"Zhang","year":"2013","journal-title":"Am. J. Med. Sci."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X15001819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X15001819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T17:14:01Z","timestamp":1717953241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X15001819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0924977X15001819"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2015.06.011","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second-generation antipsychotics and adiponectin levels in schizophrenia: A comparative meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2015.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}